Clinical Efficacy Endpoints from the Phase 3 CANOPY Study Evaluating[...]
Pharmacokinetics and Serum Virus Neutralizing Antibody Titers Following[...]
05/06/2024 | Press release | Distributed by Public on 05/06/2024 03:46
Please select the service you want to use:
Smartlinks | Smartcraft ASA | News | Politics and Policy | Company News | Shareholders | Shareholder Meeting | Stock Options | Information Technology | Software | Securities Issuers | Software Companies | Frankfurt Stock Exchange | Munich Stock Exchange | Stuttgart Stock Exchange | Euronext Oslo | Nasdaq Stockholm | Cboe Off Exchange
Copyright ©2006-2024 Public Technologies Inc. | Privacy Policy | Terms of Use | Contact